{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"44","value":"64.88"},{"groupId":"OG001","spread":"20.8","value":"129.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"description":"Cmax was defined as the maximum serum concentration of pembrolizumab reached after first dose. Blood samples were collected at pre-specified timepoints for the determination of Cmax. Per protocol, geometric mean Cmax value of pembrolizumab after the first dose of pembrolizumab formulated with berahyaluronidase alfa in arm 1 and after first dose of pembrolizumab in arm 2 was presented.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy.","id":"OG000","title":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy"},{"description":"Participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion in combination with platinum doublet chemotherapy.","id":"OG001","title":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received a dose in Cycle 1 with at least 1 valid postdose PK sample available in Cycle 1 and for whom a model-based assessment of Cmax could be made.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)","title":"Cycle 1: Maximum Serum Concentration (Cmax) of Pembrolizumab After the First Dose","type":"SECONDARY","unitOfMeasure":"μg/mL"}